U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812104) titled 'Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia' on Dec. 23, 2024.
Brief Summary: This is the first in human study of KK2845. This trial consists of Part 1 (Dose escalation) and Part 2 (Backfill). In Part 1, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2845 in patients with relapsed or refractory acute myeloid leukemia. Part 2 will collect additional data at tolerated doses of KK2845.
Study Start Date: Oct. 10, 2024
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Acute Myeloid Leukemia
Intervention:
DRUG: KK2845...